Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.

Abstract:

BACKGROUND AND OBJECTIVES:Currently evidence about clinical and demographic predictors of response to newer antidepressants such as duloxetine is limited. This study aimed to investigate whether a number of predictors, particularly co-morbid anxiety disorders and anxious depression, are associated with clinical improvement. METHODS:One hundred and one outpatients suffering from major depression (MD) were treated with duloxetine and assessed at baseline and at weeks 2, 4 and 8 on the 21-item Hamilton Depression Rating Scale (HDRS) and at weeks 4 and 8 on the Clinical Global Impression-Severity (CGI-S) scale. RESULTS:Patients with co-morbid panic disorder or obsessive-compulsive disorder showed slowed improvements at 2 and 4 weeks compared with patients without such co-morbidities; however, they showed slightly higher or similar improvements, respectively, at 8 weeks. Also, anxious MD patients showed higher improvements compared with non-anxious MD patients at all time points, with the difference between groups increasing over time. Several other predictors, such as co-morbid premenstrual dysphoric disorder and lifetime generalized anxiety disorder, were also identified. CONCLUSION:Our results suggest that co-morbidity with an anxiety disorder could negatively influence improvement following duloxetine treatment in the short term but that such a difference could be reversed by 8 weeks. However, given that the study had several limitations, including the lack of a comparison group and a flexible dosage design, further research is needed to replicate and extend these findings.

journal_name

Clin Drug Investig

authors

Nasso ED,Chiesa A,Serretti A,De Ronchi D,Mencacci C

doi

10.2165/11588800-000000000-00000

subject

Has Abstract

pub_date

2011-01-01 00:00:00

pages

385-405

issue

6

eissn

1173-2563

issn

1179-1918

journal_volume

31

pub_type

临床试验,杂志文章
  • Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone.

    abstract:BACKGROUND AND OBJECTIVES:The time-course when changes in glycemic control and body weight were first manifest in patients with type 2 diabetes mellitus (T2DM) treated with a combination of insulin degludec and liraglutide (IDegLira) was assessed, comparing IDegLira to its individual components. METHODS:Data from week...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-016-0376-0

    authors: Vilsbøll T,Vora J,Jarlov H,Kvist K,Blonde L

    更新日期:2016-04-01 00:00:00

  • Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.

    abstract:BACKGROUND AND OBJECTIVES:The standard of care for HIV treatment is a three-drug regimen consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and either a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor (PI) or an integrase strand transfer inhibitor. Darunavir boosted with ritonavi...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-016-0456-1

    authors: Lackey P,Mills A,Carpio F,Hsu R,DeJesus E,Pierone G,Henegar C,Fusco J,Fusco G,Wohlfeiler M

    更新日期:2017-01-01 00:00:00

  • HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial.

    abstract:BACKGROUND AND OBJECTIVE:The use of low levels of visible or near infrared light for reducing pain, inflammation and oedema, promoting healing of wounds, deeper tissue and nerves, and preventing tissue damage has been known for almost 40 years since the invention of lasers. The HairMax LaserComb is a hand-held Class 3R...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200929050-00001

    authors: Leavitt M,Charles G,Heyman E,Michaels D

    更新日期:2009-01-01 00:00:00

  • Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.

    abstract:BACKGROUND:Dutasteride is a dual inhibitor of type I and type II 5α-reductases and provides nearly complete suppression of dihydrotestosterone, which plays a key role in the aetiology and development of benign prostatic hyperplasia (BPH). Most knowledge about the efficacy and safety of dutasteride in BPH derives from t...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/11593750-000000000-00000

    authors: Na Y,Ye Z,Zhang S,Chinese Dutasteride Phase III Trial (ARIA108898) Study Group.

    更新日期:2012-01-01 00:00:00

  • Observational Safety Study of Clottafact® Fibrinogen Concentrate: Real-World Data in Mexico.

    abstract:BACKGROUND AND OBJECTIVE:The use of fibrinogen concentrate to treat or prevent major bleeding with regard to potential adverse reactions has not been free of controversy. Our objective was to perform a post-authorization safety study to describe the use of Clottafact® (LFB Biomedicaments) fibrinogen concentrate in real...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00906-6

    authors: Colin-Bracamontes I,Pérez-Calatayud ÁA,Carrillo-Esper R,Rodríguez-Ayala E,Padilla-Molina M,Posadas-Nava A,Olvera-Vázquez S,Hernández-Salgado L

    更新日期:2020-05-01 00:00:00

  • Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study.

    abstract:BACKGROUND:Congestion is the main cause of morbidity in patients with heart failure. Treatment of fluid overload is often challenging in everyday clinical practice. OBJECTIVE:The aim of this study was to determine the diuretic effect of acetazolamide in patients with exacerbations of chronic heart failure, in addition...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-017-0577-1

    authors: Imiela T,Budaj A

    更新日期:2017-12-01 00:00:00

  • The Association between Polypharmacy and Hip Fracture in Osteoporotic Women: A Nested Case-Control Study in South Korea.

    abstract:BACKGROUND AND OBJECTIVE:Polypharmacy, regarded as an indicator of potentially inappropriate medications (PIMs), may lead to a higher risk of serious health consequences in elderly patients with osteoporosis. Thus, this study aimed to analyze the association between polypharmacy and hip fracture in patients with osteop...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0716-3

    authors: Park HY,Kim S,Sohn HS,Kwon JW

    更新日期:2019-01-01 00:00:00

  • Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.

    abstract:BACKGROUND AND OBJECTIVE:Several antiviral therapies are now available for patients with chronic hepatitis B (CHB), but the most cost-effective strategy for Chinese patients is unclear. The aim of this study was to estimate the long-term cost effectiveness of the antiviral treatments (lamivudine, adefovir, telbivudine ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0273-y

    authors: Zhang C,Ke W,Gao Y,Zhou S,Liu L,Ye X,Yao Z,Yang Y

    更新日期:2015-03-01 00:00:00

  • Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

    abstract:BACKGROUND AND OBJECTIVES:Dyslipidaemia is a major cardiovascular risk factor associated with type 2 diabetes mellitus. Saroglitazar (ZYH1) is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity. It has been developed for the treatment of dyslipidaemia an...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-013-0128-3

    authors: Jani RH,Kansagra K,Jain MR,Patel H

    更新日期:2013-11-01 00:00:00

  • Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

    abstract:BACKGROUND AND OBJECTIVE:Concerns that antiepileptic brand-to-generic interchange results in disruption of seizure control are widespread. The objective of this study was to evaluate the safety and tolerability of the brand-to-generic levetiracetam switch in patients with focal or generalized epilepsy. METHODS:A prosp...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-015-0351-1

    authors: Vari MS,Pinto F,Mencaroni E,Giudizioso G,Minetti C,La Neve A,Francavilla T,Piccioli M,Striano S,del Gaudio L,Tovo P,Striano P,Verrotti A

    更新日期:2016-01-01 00:00:00

  • Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects.

    abstract:BACKGROUND AND OBJECTIVE:Following oral administration of abiraterone acetate, the parent compound abiraterone acetate is rapidly metabolized to abiraterone. To our knowledge, bioanalytical methods to date have not been able to detect the parent compound in human plasma, and bioassay was only performed on the metabolit...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40261-019-00752-1

    authors: Bouhajib M,Tayab Z

    更新日期:2019-03-01 00:00:00

  • Role of lormetazepam in the treatment of insomnia in the elderly.

    abstract:BACKGROUND AND OBJECTIVE:Sleep architecture changes with age, both in terms of efficiency and total duration of sleep. Hypnotic benzodiazepines promote rapid onset of sleep, uninterrupted sleep and longer duration of sleep in the absence of carryover sedation the following morning; therefore, these may be appropriate f...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200727050-00003

    authors: De Vanna M,Rubiera M,Onor ML,Aguglia E

    更新日期:2007-01-01 00:00:00

  • Effectiveness of an Intervention to Improve Management of COPD using the AUDIT Methodology: Results of the Neumo-Advance Study.

    abstract:BACKGROUND AND OBJECTIVE:The implementation of chronic obstructive pulmonary disease (COPD) guidelines in the real-world setting remains low. Pulmonologists should participate in the new paradigms of chronicity of COPD, by providing their knowledge, expertise, innovation and research. The objective of this study was to...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-019-00787-4

    authors: de Miguel-Díez J,Jiménez-García R,López de Andrés A,Zaragoza Arnáez F

    更新日期:2019-07-01 00:00:00

  • Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study.

    abstract:BACKGROUND AND OBJECTIVE:There is a general concern about the use of multisource (generic) antibacterials in the clinical setting with registration based solely on bioequivalence data. In order to address this concern, two modified-release formulations of clarithromycin (i.e. the originator Klacid XL and the generic Kl...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200929040-00005

    authors: Snyman JR,Schoeman HS,Grobusch MP,Henning M,Rabie W,Hira M,Parshotam K,Mithal Y,Singh S,Ramdas Z

    更新日期:2009-01-01 00:00:00

  • The effect of active vitamin D administration on muscle mass in hemodialysis patients.

    abstract:BACKGROUND:Muscle wasting is common and insidious in end-stage renal disease (ESRD). Loss of muscle quantity and quality reduces quality of life and increases mortality in ESRD patients. Additionally, secondary hyperparathyroidism (SHPT) causes muscle atrophy. Meanwhile, vitamin D, which is used for SHPT treatment, pla...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-013-0132-7

    authors: Mori A,Nishino T,Obata Y,Nakazawa M,Hirose M,Yamashita H,Uramatsu T,Shinzato K,Kohno S

    更新日期:2013-11-01 00:00:00

  • Barriers to pain management: focus on opioid therapy.

    abstract::Despite the availability of effective pain treatments, there are numerous barriers to effective management resulting in a large proportion of patients not achieving optimal pain control. Chronic pain is inadequately treated because of a combination of cultural, societal, educational, political and religious constraint...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11630040-000000000-00000

    authors: Zuccaro SM,Vellucci R,Sarzi-Puttini P,Cherubino P,Labianca R,Fornasari D

    更新日期:2012-02-22 00:00:00

  • Consumption and distribution of propofol in anaesthesia and intensive care use in Finland.

    abstract:BACKGROUND:Propofol is approved both for anaesthesia and sedation during intensive care. Serious adverse reactions with propofol have recently been reported, but patient exposure to the drug is unknown. OBJECTIVE:To investigate the consumption of propofol in Finnish hospitals and to develop a denominator to estimate p...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323010-00003

    authors: Kokki H,Närhi U

    更新日期:2003-01-01 00:00:00

  • Long-term chelation therapy with deferasirox: effects on cardiac iron overload measured by T2* MRI.

    abstract::We report the long-term effects of deferasirox 10-30 mg/kg/day on cardiac iron overload in a case series of five patients with transfusion-dependent beta-thalassaemia major who underwent up to 5 years of chelation therapy. Iron overload was monitored by multislice multi-echo T2* magnetic resonance imaging (MRI). Overa...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11534480-000000000-00000

    authors: Ruffo GB,Borsellino Z,Cuccia L,Marocco MR,Gagliardotto F,Tarantino R

    更新日期:2010-01-01 00:00:00

  • Ambroxol lozenge bioavailability : an open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy thai volunteers.

    abstract:OBJECTIVE:To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. DESIGN:Open-label, two-way crossover study. METHOD:Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200323040-00007

    authors: Rojpibulstit M,Kasiwong S,Juthong S,Phadoongsombat N,Faroongsarng D

    更新日期:2003-01-01 00:00:00

  • Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study.

    abstract:BACKGROUND AND OBJECTIVES:Herpes zoster (HZ) and its most frequent complication, post-herpetic neuralgia (PHN), have been shown to considerably impact quality of life (QoL). This has not yet been demonstrated in Japan. METHODS:QoL in HZ and PHN patients was evaluated using the Zoster Brief Pain Inventory (ZBPI), EuroQ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40261-017-0581-5

    authors: Mizukami A,Sato K,Adachi K,Matthews S,Holl K,Matsuki T,Kaise T,Curran D

    更新日期:2018-01-01 00:00:00

  • Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial.

    abstract:BACKGROUND AND OBJECTIVE:As a β-adrenoceptor antagonist (β-blocker), esmolol can reduce cardiac output and the phosphodiesterase III inhibitor milrinone has been shown to improve heart contractility in patients with septic shock. This study was performed to assess the effects of esmolol combined with milrinone in patie...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-015-0325-3

    authors: Wang Z,Wu Q,Nie X,Guo J,Yang C

    更新日期:2015-11-01 00:00:00

  • Clinical experience in invasive fungal infections.

    abstract::Lung infections caused by invasive filamentous fungi are very rare conditions in AIDS, but must be considered in patients with profound immune suppression especially in the presence of additional risk factors, such as hematologic malignancies, corticosteroid therapy, neutropenia, and chemotherapy. The authors report a...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-012-0017-1

    authors: Pacheco P,Ventura AS,Branco T,Gonçalves L,Carvalho C

    更新日期:2013-02-01 00:00:00

  • Hypokalaemia in healthy volunteers after single and multiple doses of formoterol or salbutamol.

    abstract::A specific beta(2)-adrenoceptor-mediated effect, hypokalaemia, was studied in healthy volunteers after single as well as multiple dosages of the long-acting agonist formoterol and the short-acting agent salbutamol. The purpose of the study was to test with simple methodologies if rapidly induced tachyphylaxis for this...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815060-00009

    authors: van den Berg BT,Louwerse RT,Luiken GJ,Jonkers RE,van Boxtel CJ

    更新日期:1998-01-01 00:00:00

  • Opioid receptors and myocardial protection: do opioid agonists possess cardioprotective effects?

    abstract::In an in vivo rat model of myocardial infarction, opioid receptor stimulation has been observed to result in a reduction in infarct size similar to that produced by ischaemic preconditioning. The ability of glibenclamide to abolish this effect suggests an involvement of the myocardial ATP-sensitive potassium (K(ATP)) ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815050-00009

    authors: McCormack KJ,Chapleo CB

    更新日期:1998-01-01 00:00:00

  • Pantoprazole: a proton pump inhibitor.

    abstract::Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, n...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/1153121-S0-000000000-00000

    authors: Moreira Dias L

    更新日期:2009-01-01 00:00:00

  • Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers.

    abstract:BACKGROUND AND OBJECTIVES:Baicalein, a flavonoid isolated from the root of Scutellaria baicalensis Georgi, is a neuroprotective agent under development to treat Parkinson's disease. This study investigated the pharmacokinetics, safety and tolerability of baicalein after a multiple-ascending-dose protocol in healthy Chi...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-016-0418-7

    authors: Pang H,Xue W,Shi A,Li M,Li Y,Cao G,Yan B,Dong F,Xiao W,He G,Du G,Hu X,Cheng G

    更新日期:2016-09-01 00:00:00

  • Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model.

    abstract:BACKGROUND AND OBJECTIVE:Clinicians must choose between an increasing number of medications for the treatment of pulmonary arterial hypertension (PAH) with different routes of administration, adverse effects, costs and efficacies. We constructed a decision analysis to help inform treatment choices in PAH. METHODS:We c...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/11317820-000000000-00000

    authors: Garin MC,Clark L,Chumney EC,Simpson KN,Highland KB

    更新日期:2009-01-01 00:00:00

  • Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts.

    abstract:BACKGROUND:Cutaneous warts are caused by human papilloma virus (HPV) infection. FIT039, a specific inhibitor of CDK9, suppresses the proliferation of DNA viruses in vitro. PURPOSE:We evaluated the safety, plasma concentrations, and efficacy of FIT039 delivered by single application of an adhesive skin patch on normal ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-0712-7

    authors: Sumi E,Nomura T,Asada R,Uozumi R,Tada H,Amino Y,Sawada T,Yonezawa A,Hagiwara M,Kabashima K

    更新日期:2019-01-01 00:00:00

  • Preferential Antiseizure Medications in Pediatric Patients with Convulsive Status Epilepticus: A Systematic Review and Network Meta-Analysis.

    abstract:BACKGROUND AND OBJECTIVE:The optimal choice for first- and second-line antiseizure medications for pediatric patients with convulsive status epilepticus remains ambiguous. The present study aimed to estimate the comparative effect on the efficacy and safety of different antiseizure medications in pediatric patients wit...

    journal_title:Clinical drug investigation

    pub_type:

    doi:10.1007/s40261-020-00975-7

    authors: Zhang Y,Liu Y,Liao Q,Liu Z

    更新日期:2021-01-01 00:00:00

  • Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective.

    abstract:PURPOSE:Deferiprone (DFP), deferasirox (DFX) and deferoxamine (DFO) are used in thalassaemia major (TM) patients to treat chronic iron overload. We evaluated the cost-effectiveness of DFP, compared with DFX and DFO monotherapy, from an Italian healthcare system perspective. METHODS:A Markov model was used over a time ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0496-1

    authors: Pepe A,Rossi G,Bentley A,Putti MC,Frizziero L,D'Ascola DG,Cuccia L,Spasiano A,Filosa A,Caruso V,Hanif A,Meloni A

    更新日期:2017-05-01 00:00:00